normal, regular bowel movements and to have no gastrointestinal symptoms. Exclusion criteria 23 for donors included body mass index (BMI) > 30, antibiotic use in the past 6 months, chronic 24 disease or abnormal screening results. Following a clinical examination at the outpatient clinic, 25 donors were screened for various transmittable diseases. Serological screening included testing 26 for hepatitis A, B and C, HIV-1 and 2 and Treponema pallidum. Donor stools were screened by 27 culturing for the presence of Salmonella spp., Shigella spp., Yersinia enterocolitica, Yersinia 28 pseudotuberculosis, Campylobacter spp., Clostridium difficile and Aeromonas spp. Additionally, 29 specific screening for antibiotic-resistant strains was performed using the active detection of 30 carbapenemase-producing Enterobacteriaceae (CPE) and extended spectrum beta-lactamase 31 (ESBL) producing organisms. Microscopic examination was performed to confirm the absence of 32 2 eggs, cysts and/or larvae of parasites, and the presence of Clostridium difficile toxins A and B 33 was screened using an enzyme immuno-assay. 34
35

FMT procedure 36
Fresh donor stools were collected on the day of transplantation, stored at 4°C and processed 37 within 6 hours, as previously described. [1] Briefly, 300 mL of 0.9% NaCl was added to the stool 38 sample and thoroughly mixed using a handheld blender. The resulting suspension was filtered 39 and transferred into 60 mL syringes. All procedures were performed under laminar airflow 40
conditions. Prior to transplantation, patients underwent a bowel preparation using macrogol. The 
Evaluation of clinical endpoints 58
IBS-related symptoms were assessed using a daily symptom diary (supplementary table 1) that 59 evaluated general abdominal discomfort, abdominal bloating, abdominal pain and flatulence on a 60 scale of one to six. In addition, the number of daily bowel movements, the consistency of the 61 stools and the abdominal circumference (measured at the umbilicus by patients themselves at 62 exactly the same time every day) were assessed as well. Quality of life was assessed using a 63 standardized, IBS-specific quality of life questionnaire (IBS-QoL) in the patient's native 64 language.
3 66
Microbiome analysis 67
Consecutive faecal samples were collected for microbiome analyses. Stool samples of patients 68 and donors were collected before the FMT (at baseline) and at selected time-points after 69 treatment. Samples were immediately stored at -20°C and transferred to -80°C within one week. 70 DNA was extracted from the frozen faecal samples using the PowerMicrobiome RNA Isolation 71 Kit (MOBIO Laboratories Inc.) as previously described. 
16S data processing 77
Sequence analysis was performed according to Geirnaert and colleagues.
[4] FLASH 16 -merged 78 sequences were subject to quality filtering using the FASTX-toolkit, and chimaera removal was 79 performed using UCHIME. [5,6] Samples were rarefied to 10,000 reads; then, the taxonomical 80 classifications of sequences were performed using an RDP classifier [7] to generate phylum to 81 genus level composition matrices. Bootstrap values from the RDP classifier were used to identify 82 sequences with high-confidence genus assignments (bootstrap value >0.8), whereas sequences 83 classified with lower confidence were binned at the family level (labelled unclassified family). A 84 species-level matrix was generated using de novo OTU clustering with the UPARSE pipeline [8] 85
and a 97% identity threshold. 86
87
Statistical analysis 88
Statistical analysis was performed using SPSS Statistics version 22 (Chicago, USA). Wilcoxon 89 signed ranks test and the Mann-Whitney U test were used for analysis of paired and non-paired 90 data, respectively. Two-tailed probabilities were calculated and p-values of less than 0.05 were 91 considered statistically significant. 
